GeneDx Holdings (WGS) Accumulated Expenses (2020 - 2026)

GeneDx Holdings (WGS) has reported Accumulated Expenses for 7 consecutive years, with $30.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 7.43% year-over-year to $30.2 million in Q2 2026; TTM through Jun 2026 was $30.2 million, a 7.43% increase from a year earlier, with the FY2025 full-year figure at $44.7 million, up 258.91% from the prior year.
• Accumulated Expenses was $30.2 million for Q2 2026 at GeneDx Holdings, up from $24.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $44.7 million in Q4 2025 and troughed at $7.3 million in Q2 2024.
• A 5-year average of $20.6 million and a median of $20.3 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 59.04% in 2024 and soared 285.52% in 2025, its largest moves.
• Over 5 years, Accumulated Expenses stood at $20.3 million in 2022, then plunged by 40.05% to $12.2 million in 2023, then rose by 2.17% to $12.4 million in 2024, then soared by 258.91% to $44.7 million in 2025, then slumped by 32.37% to $30.2 million in 2026.
• The last three Accumulated Expenses figures came in at $30.2 million (Q2 2026), $24.7 million (Q1 2026), and $44.7 million (Q4 2025), per Business Quant data.